ProCE Banner Activity

EV-201: Enfortumab Vedotin in Advanced Urothelial Cancer Previously Treated With Platinum Chemotherapy and Immune Checkpoint Inhibitors

Slideset Download
Conference Coverage
EV-201 data showed a response rate of 44% with enfortumab vedotin in patients with advanced urothelial cancer who progressed after platinum chemotherapy and checkpoint inhibitors.

Released: June 07, 2019

Expiration: June 05, 2020

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro